إيطاليا -
الإيطالية -
Ministero della Salute
gaster
acme s.r.l. - omeprazolo - omeprazolo - 343 mg - omeprazole
إيطاليا -
الإيطالية -
Ministero della Salute
halien
acme s.r.l. - ialuronato sodico - ialuronato sodico - 17 milligrammo (i), ialuronato sodico - 17 mg - hyaluronic acid
إيطاليا -
الإيطالية -
Ministero della Salute
socatil
acme s.r.l. - formosulfatiazolo - formosulfatiazolo - 7.5 grammo (i), formosulfatiazolo - 7.5 g, formosulfatiazolo - nd, formosulfatiazolo - 50 g - formosulfathiazole
إيطاليا -
الإيطالية -
Ministero della Salute
demicol
ceva salute animale s.p.a. - miconazolo - miconazolo - 100 mg - miconazole
إيطاليا -
الإيطالية -
Ministero della Salute
bute
acme s.r.l. - fenilbutazone - fenilbutazone - 8 grammo (i), fenilbutazone sodico - 20 grammo (i) ; fenilbutazone - nd, fenilbutazone sodico - nd ; fenilbutazone - 2 grammo (i), fenilbutazone sodico - nd ; fenilbutazone - 8 g, fenilbutazone - 2 g; fenilbutazone sodico - nd, fenilbutazone - nd ; fenilbutazone sodico - 20 g, fenilbutazone sodico - nd ; fenilbutazone - 2 g - phenylbutazone
إيطاليا -
الإيطالية -
Ministero della Salute
ovistop
acme drugs s.r.l. - nicarbazina - nicarbazina - 0.08 g - nicarbazine
إيطاليا -
الإيطالية -
Ministero della Salute
avalon
acme s.r.l. - ivermectina - ivermectina - 1.87 grammo (i), ivermectina - 1.87 g - ivermectin
إيطاليا -
الإيطالية -
Ministero della Salute
nargesic
acme s.r.l. - butorfanolo tartrato - butorfanolo tartrato - 14.58 milligrammo (i), butorfanolo tartrato - 14.58 mg - butorphanol
إيطاليا -
الإيطالية -
Ministero della Salute
vetemucil granulato
acme s.r.l. - acetilcisteina - acetilcisteina - 1 g - acetylcysteine
الاتحاد الأوروبي -
الإيطالية -
EMA (European Medicines Agency)
skyrizi
abbvie deutschland gmbh & co. kg - risankizumab - psoriasis; arthritis, psoriatic - immunosoppressori - plaque psoriasisskyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisskyrizi, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). crohn's diseaseskyrizi is indicated for the treatment of adult patients with moderately to severely active crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.